Research
Good Bacteria
Part 1
Probiotic effects on faecal inflammatory markers and
on faecal IgA in food allergic atopic eczema/dermatitis
syndrome infants
Abstract
Viljanen
M, Kuitunen M, Haahtela T, Juntunen-Backman K, Korpela
R, Savilahti E.
The
Skin and Allergy Hospital, University of Helsinki, Helsinki,
Finland.
Probiotic
bacteria are proposed to alleviate intestinal inflammation
in infants with atopic eczema/dermatitis syndrome (AEDS)
and food allergy. In such infants we investigated effects
of probiotic bacteria on faecal IgA, and on the intestinal
inflammation markers tumour necrosis factor-alpha (TNF-alpha),
alpha1-antitrypsin (AT), and eosinophil cationic protein
(ECP). A total of 230 infants with AEDS and suspected
cow's milk allergy (CMA) received in a randomized double-blinded
manner, concomitant with elimination diet, Lactobacillus
GG (LGG), a mixture of four probiotic strains (MIX),
or placebo for 4 wk. Four weeks after treatment, CMA
was diagnosed with a double-blind placebo-controlled
milk challenge. Faecal samples of 102 infants, randomly
chosen for analysis, were collected before treatment,
after 4-wk treatment, and on the first day of milk challenge.
After treatment, IgA levels tended to be higher in probiotic
groups than in the placebo group (LGG vs. placebo, p=0.064;
MIX vs. placebo, p=0.064), and AT decreased in the LGG
group, but not in other treatment groups. After challenge
in IgE-associated CMA infants, faecal IgA was higher
for LGG than for placebo (p=0.014), and TNF-alpha was
lower for LGG than for placebo, but non-significantly
(p=0.111). In conclusion, 4-wk treatment with LGG may
alleviate intestinal inflammation in infants with AEDS
and CMA.